RELAXMEDIX ®



APPLICATIONS

- Relaxation/Sleep Support
- Stress Management Support
- Immune System Support
- Inflammatory Response Support
- Neurological Support



INTRODUCTION

RelaxMedix is a proprietary blend of hydro-ethanol extracts from Valerian root (Valeriana officinalis) and Cat's Claw bark (Uncaria tomentosa), also known as Samento. Constituents of V. officinalis include, among others, the sesquiterpene valerenic acid and iridoid valepotriates. V. officinalis and its constituent valerenic acid may act as a GABA agonist as well as a partial HT agonist.^{2,3,4,5} V. officinalis may also act as an A₁ receptor agonist.^{*6} Activity at these receptors may account for valerian's role in the support of relaxation, sleep, and a healthy stress response.* Samento is extracted from the rare pentacyclic chemotype of *U. tomentosa*, which is TOA-free. This pentacyclic oxindole alkaloid (POA)-predominant, tetracyclic oxindole alkaloid (TOA)-free form of *U. tomentosa* may help with immune system support and inflammatory response support.*7,8

RelaxMedix is made at our U.S. manufacturing facility using a specialized proprietary extraction process that optimizes the constituents of the herbs in their original, unprocessed state to obtain broad-spectrum concentration. Because our extracts are made in our own facility, we control all aspects of quality, including stringent ID testing, microbial testing, and heavy metal testing. NutraMedix rigorously follows current good manufacturing practices (cGMP), as do our suppliers.

RELAXATION/SLEEP SUPPORT

According to a recent systematic review and meta-analysis of human trials, V. officinalis may help to support relaxation and sleep in occasional sleeplessness.*6 It may help to support both quality and quantity of sleep, with fewer nighttime awakenings.*9 V. officinalis may also support sleep through skeletal muscle relaxation, as seen in a mouse study.*4

STRESS MANAGEMENT SUPPORT

Valerian may help with stress management support during occasional stress.*10 One human trial with healthy individuals compared the effects of valerian alone, kava alone, and no treatment, on mental stress during cognitive testing. All three groups underwent initial cognitive testing, then were administered either valerian, kava, or nothing for 7 days. All three groups then underwent a subsequent session of cognitive testing. While both the valerian and kava groups experienced a decrease in systolic blood pressure after the intervention, only the valerian group experienced a lower heart rate during mental stress. While neither intervention affected performance, it appeared to mitigate the perception of mental stress by decreasing physiological reactivity.*¹⁰ A similar decrease in physiological reactivity was seen in a separate randomized, controlled trial.*¹¹ In mice, one study found that constituent valepotriates may help to support healthy stress management, which a rat study attributed to modulation of the HPA axis.*¹² As shown in a mouse study, *U. tomentosa* may also help to support stress management. *13

OTHER USES

Immune System Support *U. tomentosa* (pentacyclic chemotype) may help to maintain a healthy immune response and support immune system homeostasis.* *U. tomentosa* may help to maintain neutrophil function as well as Th1 and Th2 levels already within the normal ranges.* 13,14,15 It should be noted that only TOA-free *U. tomentosa* (such as Samento) helps with immune support.*7

Together, *V. officinalis* and *U. tomentosa* have synergistic effects.* It is known that both stress and insufficient sleep have depressant effects on the immune system.¹⁶ V. officinalis may help to maintain immune system health through the support of relaxation and sleep, while TOA-free *U. tomentosa* (pentacyclic chemotype) may help to support immune system health more directly.⁷⁷

Inflammatory Response Support

U. tomentosa (pentacyclic chemotype) may help to maintain a healthy inflammatory response.*8,17 It may help to support NF-kappa B levels already within the normal range in a dose-dependent manner,18,19 thus supporting both TNF-alpha and IL-1-beta within the normal ranges.*18

Neurological Support

U. tomentosa may help to support neurological health and help to maintain healthy neurocognitive function.*20,2

SAFETY AND CAUTIONS

V. officinalis (root) is generally well tolerated. Common side effects include drowsiness, dizziness, and occasional gastrointestinal effects. As *V. officinalis* supports relaxation, it may have additive effects when taken with sedative substances such as alcohol, berzodiazepines, and occasional gastrointestinal effects. As *V. officinalis* supports relaxation, it may have additive effects when taken with sedative substances such as alcohol, berzodiazepines, and occasional substances such as alcohol, berzodiazepines, and ugraphical substances with substances and ugraphical substances of drugs metabolized by Ugraphical ugraphical substances of hepatoxicity, particularly in higher doses, with multi-ingredient formulas, or concurrent with alcohol abuse. We officinalis is considered as a recommended doses for shorter periods. In extended use, it should be tanggrad rather than stronged abrustly to avoid rehound effects. should be tapered rather than stopped abruptly, to avoid rebound effects.²

U. tomentosa (bark) is generally well tolerated. Gastrointestinal effects such as nausea, vomiting, constipation and diarrhea have been reported. ²⁸ It should be avoided in those taking immunosuppressants, as it may interfere with immunosuppressant therapy. **J. tomentosa* may inhibit P450 CYP3A4 enzymes and therefore may slow the metabolism of drugs metabolized by CYP3A4. **J. tomentosa* may have additive effects with anticoagulants, generally attributed to the TOA rhynchophylline, **Ja* sa well as additive effects with antihypertensive drugs, generally attributed to the TOAs rhynchophylline and isorhynchophylline. **Ja* sa a reminder, camento is TOA free. Samento is TOA-free.

Safety not documented in breastfeeding or pregnant women, or in children under 3 years of age due to insufficient safety research.

* This statement has not been evaluated by the Food and Drug Administration. This product is not intended to treat, cure, or prevent any diseases.



REFERENCES

33 Zhou, J. Y., & Zhou, S. W. (2012). Fitoterapia, 83(4), 617–626.

¹ Pilerood, S. A. & Prakash, J. (2013). *International Journal of Food, Nutrition, and Dietetics*, 1(1). ² Dietz, B. M., Mahady, G. B., et al. (2005). Brain Research Molecular Brain Research, 138(2), 191–197. ³ Benke, D., Barberis, A., et al. (2009). *Neuropharmacology*, 56(1), 174–181. 4 Caudal, D., Guinobert, I., et al. (2017). Journal of Traditional and Complementary Medicine, 8(2), 335–340. ⁵ Gordan, A., Taheri, E., & Saeidi, J. (2019). Journal of Pharmaceutical Research International, 29 (2), 1-10. ⁶ Shinjyo, N., Waddell, G., & Green, J. (2020). Journal of Evidence-Based Integrative Medicine, 25, 2515690X20967323. 7 Batiha, G. E.-S., Magdy Beshbishy, A., et al. (2020). Applied Sciences, 10(8), 2668. 8 Liang, J. H., Wang, C., et al. (2020). Fitoterapia, 147, 104772. 9 Abdellah, S. A., Berlin, A., et al. (2019). Journal of Traditional and Complementary Medicine, 10(2), 116–123. ¹⁰ Cropley, M., Cave, Z., et al. (2002). *Phytotherapy Research: PTR*, 16(1), 23–27. ¹¹ Mineo, L., Concerto, C., et al. (2017). *Neuropsychobiology*, 75(1), 46–51. ¹² Shi, S. N., Shi, J. L., et al. (2014). Evidence-Based Complementary and Alternative Medicine: eCAM, 2014, 325948. ¹³ Bigliani, M. C., Rosso, M. C., et al. (2013). *Natural Product Research*, 27(18), 1682–1685.

¹⁴ Montserrat-de la Paz, S., Fernandez-Arche, A., et al. (2016). *Phytomedicine: International journal of phytotherapy and phytopharmacology*, 23(2), 141–148. 15 Núñez, C., Lozada-Requena, I., et al. (2015). Revista Peruana de Medicina Experimental y Salud Publica, 32(4), 643-651. ¹⁶ Asif, N., Iqbal, R., & Nazir, C. F. (2017). American Journal of Clinical and Experimental Immunology, 6(6), 92–96. ¹⁷ Mur, E., Hartig, F., et al. (2002). The Journal of Rheumatology, 29(4), 678–681. 18 Sandoval-Chacón, M., Thompson, J. H., et al. (1998). Alimentary Pharmacology & Therapeutics, 12(12), 1279–1289. ¹⁹ Allen-Hall, L., Arnason, J. T., et al. (2010). *Journal of Ethnopharmacology*, 127(3), 685–693. ²⁰ Snow, A. D., Castillo, G. M., et al. (2019). *Scientific Reports*, 9(1), 561. ²¹ Mohamed, A. F., Matsumoto, K., et al. (2000). The Journal of Pharmacy and Pharmacology, 52(12), 1553–1561. ²² Hadley, S., & Petry, J. J. (2003). *American Family Physician*, 67(8), 1755–1758. ²³ Chen, D., Klesmer, J., et al. (2002). *The American Journal on Addictions*, 11(1), 75–77.

²⁴ Donovan, J. L., DeVane, C. L., et al. (2004). *Drug Metabolism and Disposition: The biological fate of chemicals*, 32(12), 1333–1336. ²⁵ Houghton P. J. (1999). *The Journal of Pharmacy and Pharmacology*, 51(5), 505–512. Alkharfy, K. M., & Frye, R. F. (2007). Xenobiotica: The fate of foreign compounds in biological systems, 37(2), 113–123.
 Natural Medicines. (2021, March 20). Valerian [monograph]. http://naturalmedicines.therapeuticresearch.com. ²⁸ de Paula, L. C., Fonseca, F., et al. (2015). Journal of Alternative and Complementary Medicine (New York, N.Y.), 21(1), 22–30. ²⁹ Lamm, S., Sheng, Y., & Pero, R. W. (2001). Phytomedicine: International journal of phytotherapy and phytopharmacology, 8(4), 267–274. ³⁰ Budzinski, J. W., Foster, B. C., et al. (2000). Phytomedicine: International journal of phytotherapy and phytopharmacology, 7(4), 273–282. ³¹ Chen, C. X., Jin, R. M., et al. (1992). Zhongguo yao li xue bao = Acta Pharmacologica Sinica, 13(2), 126–130. ³² Zhou, J., & Zhou, S. (2010). Journal of Ethnopharmacology, 132(1), 15–27.